The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Open accessAbstract
BACKGROUND: Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a selective inhibitor of this kinase. METHODS: A total of 532 patients with late--chronic-phase CML in whom previous therapy with interferon alfa had failed were treated with 400 mg of oral imatinib daily. Patients were evaluated for cytogenetic and hematologic responses. Time to progression, survival, and toxic effects were also evaluated. RESULTS: Imatinib induced major cytogenetic responses in 60 percent of the 454 patients with confirmed chronic-phase CML and complete hematologic responses in 95 percent. After a median follow-up of 18 months, CML had not progressed to the accelerated or blast phases in an estimated 89 percent of patients, and 95 percent of the patients were alive. Grade 3 or 4 nonhematologic toxic effects were infrequent, and hematologic toxic effects were manageable. Only 2 percent of patients discontinued treatment because of drug-related adverse events, and no treatment-related deaths occurred. CONCLUSIONS: Imatinib induced high rates of cytogenetic and hematologic responses in patients with chronic-phase CML in whom previous interferon therapy had failed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Self-citationROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Self-citationDruker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Self-citationA minute chromosome in human chronic granulocytic leukemia
Nowell̀, P. C. (1960) · Science · Cited by 2,269
Daley, G. Q., Van Etten, R. A., & Baltimore, D. (1990) · Science · doi:10.1126/science.2406902 · Cited by 1,756
Sawyers, C. L. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401706 · Cited by 1,621
Self-citationDruker, B. J., & Lydon, N. B. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9083 · Cited by 707
Self-citationAcute leukaemia in bcr/abl transgenic mice
Heisterkamp, N., Jenster, G., ten Hoeve, J., Zovich, D., Pattengale, P. K., & Groffen, J. (1990) · Nature · doi:10.1038/344251a0 · Cited by 672
Interferon Alfa-2b Combined with Cytarabine versus Interferon Alone in Chronic Myelogenous Leukemia
Guilhot, F., Chastang, C., Michallet, M., Guerci, A., Harousseau, J.-L., Maloisel, F., Bouabdallah, R., Guyotat, D., Cheron, N., Nicolini, F., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707243370402 · Cited by 543
Self-citationInduction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.
Kelliher, M. A., McLaughlin, J., Witte, O. N., & Rosenberg, N. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.17.6649 · Cited by 514
The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
Deininger, M. W. N., Goldman, J. M., Lydon, N., & Melo, J. V. (1997) · Blood · doi:10.1182/blood.v90.9.3691 · Cited by 482
Silver, R. T., Woolf, S. H., Hehlmann, R., Appelbaum, F. R., Anderson, J., Bennett, C., Goldman, J. M., Guilhot, F., Kantarjian, H. M., Lichtin, A. E., et al. (1999) · PubMed · Cited by 463
Self-citationChronic Myelogenous Leukemia: Biology and Therapy
Faderl, S., Talpaz, M., Estrov, Z., & Kantarjian, H. M. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-3-199908030-00008 · Cited by 462
Self-citationChronic myelogenous leukemia: a concise update
Kantarjian, H., Deisseroth, A., Kurzrock, R., Estrov, Z., & Talpaz, M. (1993) · Blood · doi:10.1182/blood.v82.3.691.691 · Cited by 449
Self-citationIn Vivo Eradication of Human BCR/ABL-Positive Leukemia Cells With an ABL Kinase Inhibitor
le Coutre, P., Mologni, L., Cleris, L., Marchesi, E., Buchdunger, E., Giardini, R., Formelli, F., & Gambacorti-Passerini, C. (1999) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/91.2.163 · Cited by 374
Self-citationElefanty, A. G., Hariharan, I. K., & Cory, S. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb08212.x · Cited by 344
Gambacorti-Passerini, C., le Coutre, P., Mologni, L., Fanelli, M., Bertazzoli, C., Marchesi, E., Di Nicola, M., Biondi, A., Corneo, G. M., Belotti, D., et al. (1997) · Blood Cells, Molecules, and Diseases · doi:10.1006/bcmd.1997.0155 · Cited by 316
Self-citationALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKAEMIA
Speck, B., Bortin, M., Champlin, R., Goldman, J., Herzig, R., Mcglave, P., Messner, H., Weiner, R., & Rimm, A. (1984) · The Lancet · doi:10.1016/s0140-6736(84)92179-2 · Cited by 259
Chronic myeloid leukemia: current treatment options
Goldman, J. M., & Druker, B. J. (2001) · Blood · doi:10.1182/blood.v98.7.2039 · Cited by 224
Self-citationStaging and prognosis in chronic myelogenous leukemia.
Sokal, J. E., Baccarani, M., Russo, D., & Tura, S. (1988) · PubMed · Cited by 210
O'Brien, S., Kantarjian, H., Keating, M., Beran, M., Koller, C., Robertson, L., Hester, J., Rios, M., Andreeff, M., & Talpaz, M. (1995) · Blood · doi:10.1182/blood.v86.9.3322.bloodjournal8693322 · Cited by 181
Self-citationKantarjian, H. M., O'Brien, S. M., Smith, T. L., Rios, M. B., Cortes, J. E., Beran, M., Koller, C. A., Giles, F. J., Andreeff, M., Kornblau, S. M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.284 · Cited by 139
Self-citationKantarjian, H. M., Talpaz, M., Smith, T. L., Cortes, J. E., Giles, F. J., Rios, M. B., Mallard, S., Gajewski, J., Murgo, A. J., Cheson, B. D., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.20.3513 · Cited by 94
Self-citation
Cited by
O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
Self-citationFive-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Self-citationAcute Lymphoblastic Leukemia in Children
Hunger, S. P., & Mullighan, C. G. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1400972 · Cited by 2,204
Chemotherapy and the war on cancer
Chabner, B. A., & Roberts, T. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1529 · Cited by 2,154
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Self-citation
Metadata
- Authors
- Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., Talpaz, M., & Druker, B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-02-28
- Volume
- 346
- Issue
- 9
- Pages
- 645-652
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2011474502
- Cited by
- 2,019
- References
- 24
- FWCI
- 93.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.